Neurologic disorders in long-term survivors of neuroblastoma – a population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) research program. (1st February 2020)
- Record Type:
- Journal Article
- Title:
- Neurologic disorders in long-term survivors of neuroblastoma – a population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) research program. (1st February 2020)
- Main Title:
- Neurologic disorders in long-term survivors of neuroblastoma – a population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) research program
- Authors:
- Norsker, Filippa Nyboe
Rechnitzer, Catherine
Andersen, Elisabeth Wreford
Linnet, Karen Markussen
Kenborg, Line
Holmqvist, Anna Sällfors
Tryggvadottir, Laufey
Madanat-Harjuoja, Laura-Maria
Øra, Ingrid
Thorarinsdottir, Halldora K.
Vettenranta, Kim
Bautz, Andrea
Schrøder, Henrik
Hasle, Henrik
Winther, Jeanette Falck - Abstract:
- Abstract: Background: Neuroblastoma is the commonest extracranial solid tumor of childhood, yet rare, and with poor survival before 1990, especially for high-risk disease; thus, information on late effects is sparse. With great advances in cancer treatment, survival has reached 80% in the Nordic countries. The aim of the study was to investigate the risk of developing neurologic disorders after neuroblastoma. Material and methods: Through population-based cancer registries of four Nordic countries we identified 654 5-year survivors of neuroblastoma (diagnosed 1959–2008) and 133, 668 matched population comparisons. We grouped neurologic diagnoses from national hospital registries into 11 main diagnostic categories and 56 disease-specific sub-categories and calculated relative risks (RRs), absolute excess risks (AERs), cumulative incidence and mean cumulative count (MCC). Information on cancer treatment was available for 49% of survivors. Results: A hospital contact for a neurologic disorder was observed in 181 survivors 5 years or more from cancer diagnosis with 59 expected, yielding a RR of 3.1 (95% CI 2.7–3.6) and an AER of 16 per 1, 000 person-years (95% CI 12–19). The most frequent disorders included epilepsy, paralytic syndromes, diseases of the eyes and ears and hearing loss. The cumulative incidence of any neurologic disorder was 31% in survivors 20 years after cancer diagnosis with a MCC of 0.5 unique diagnoses. All risks were highest in survivors of high-riskAbstract: Background: Neuroblastoma is the commonest extracranial solid tumor of childhood, yet rare, and with poor survival before 1990, especially for high-risk disease; thus, information on late effects is sparse. With great advances in cancer treatment, survival has reached 80% in the Nordic countries. The aim of the study was to investigate the risk of developing neurologic disorders after neuroblastoma. Material and methods: Through population-based cancer registries of four Nordic countries we identified 654 5-year survivors of neuroblastoma (diagnosed 1959–2008) and 133, 668 matched population comparisons. We grouped neurologic diagnoses from national hospital registries into 11 main diagnostic categories and 56 disease-specific sub-categories and calculated relative risks (RRs), absolute excess risks (AERs), cumulative incidence and mean cumulative count (MCC). Information on cancer treatment was available for 49% of survivors. Results: A hospital contact for a neurologic disorder was observed in 181 survivors 5 years or more from cancer diagnosis with 59 expected, yielding a RR of 3.1 (95% CI 2.7–3.6) and an AER of 16 per 1, 000 person-years (95% CI 12–19). The most frequent disorders included epilepsy, paralytic syndromes, diseases of the eyes and ears and hearing loss. The cumulative incidence of any neurologic disorder was 31% in survivors 20 years after cancer diagnosis with a MCC of 0.5 unique diagnoses. All risks were highest in survivors of high-risk neuroblastoma. Conclusion: Neuroblastoma survivors represent a population with a high risk of developing neurologic disorders. Our results should contribute to improving health care planning and underscores the need for systematic follow-up care of this vulnerable group of survivors. … (more)
- Is Part Of:
- Acta oncologica. Volume 59:Number 2(2020)
- Journal:
- Acta oncologica
- Issue:
- Volume 59:Number 2(2020)
- Issue Display:
- Volume 59, Issue 2 (2020)
- Year:
- 2020
- Volume:
- 59
- Issue:
- 2
- Issue Sort Value:
- 2020-0059-0002-0000
- Page Start:
- 134
- Page End:
- 140
- Publication Date:
- 2020-02-01
- Subjects:
- Oncology -- Periodicals
Cancer -- Treatment -- Periodicals
616.992 - Journal URLs:
- http://informahealthcare.com/loi/onc ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/0284186X.2019.1672892 ↗
- Languages:
- English
- ISSNs:
- 0284-186X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0641.705000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 12893.xml